ArticleFrontiers in oncology2026

Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report.

Liping Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.